Skip to main content
Clinical Trials/NCT05609435
NCT05609435
Completed
Not Applicable

Evaluating a Novel Follow-up Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer Survivors in Wisconsin

University of Wisconsin, Madison1 site in 1 country104 target enrollmentNovember 16, 2022
ConditionsBreast Cancer
InterventionsREASSURE

Overview

Phase
Not Applicable
Intervention
REASSURE
Conditions
Breast Cancer
Sponsor
University of Wisconsin, Madison
Enrollment
104
Locations
1
Primary Endpoint
Preparing for Life as a (New) Survivor (PLANS) Scale Score: Part 1
Status
Completed
Last Updated
18 days ago

Overview

Brief Summary

This study tests a novel intervention designed to optimize needed survivorship care for low-risk breast cancer survivors while reducing burdensome care with limited health benefits. This study examines whether the intervention, titled REASSURE, improves survivors' preparedness for survivorship. Up to 110 participants will be on study for up to 18 months.

Detailed Description

The investigators plan a single site prospective, randomized, trial that will compare the effect of REASSURE on survivor preparedness against usual care. Survivors will be identified from breast oncology clinics within UW Health. REASSURE is comprised of three components: 1) the REASSURE PRO assessment, which assesses survivors' symptoms and/or concerns, 2) a recommendation for or against a follow-up visit based on survivors reported symptoms /concerns using pre-established thresholds, and 3) REASSURE survivorship messaging. * Primary Objective * Compare survivors' preparedness for survivorship with REASSURE versus usual care. * Secondary Objectives * Determine the acceptability of REASSURE for survivors living in rural and non-rural areas. * Assess changes in survivor reported symptoms and number of follow-up visits with REASSURE versus usual care.

Registry
clinicaltrials.gov
Start Date
November 16, 2022
End Date
January 27, 2026
Last Updated
18 days ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of stage I, ER and/or PR positive, her2neu negative breast cancer within the last 6-24 monoths
  • Willing to complete study procedures using email

Exclusion Criteria

  • Receipt of chemotherapy for the stage I ER and/or PR positive, her2neu negative breast cancer diagnosed within the last 6-24 months
  • Participants will be excluded if they are unable to read and write in English or if, in the opinion of a treating clinician, have cognitive impairment that would prevent completion of study procedures
  • Pregnancy, based on patient self-report. If a patient becomes pregnant during the study period, they will be removed from the study at that time.
  • Diagnosis of a ER and PR negative, her2neu negative breast cancer or a her2neu positive breast cancer within the last 5 years

Arms & Interventions

REASSURE Follow Up care

Intervention: REASSURE

Usual Follow Up Care

Outcomes

Primary Outcomes

Preparing for Life as a (New) Survivor (PLANS) Scale Score: Part 1

Time Frame: up to 18 months

Survivors' preparedness for survivorship will be assessed using Part 1 of the Preparing for Life as a (New) Survivor (PLANS) scale. This is an 11-item survey scored on a 4 point likert scale for a total possible range of score from 11 - 44 where higher scores indicate increased preparedness.

Preparing for Life as a (New) Survivor (PLANS) Scale Score: Part 2

Time Frame: up to 18 months

Survivors' confidence about follow-up will be assessed using Part 2 of the Preparing for Life as a (New) Survivor (PLANS) scale. This is a 5-item survey scored on a 10 point likert scale for a total possible range of score from 5 - 50 where higher scores indicate increased confidence.

Secondary Outcomes

  • Number of Threshold-Level Symptoms Reported on the PRO Assessment(up to 18 months)
  • Number of Follow Up Visits(up to 18 months)
  • Number of Participants In Intervention Arm who would recommend this approach to follow-up to other survivors(up to 18 months)
  • Number of Threshold-Level Symptoms Survivors Perceive are Addressed on each visit(up to 18 months)

Study Sites (1)

Loading locations...

Similar Trials